Erectile dysfunction

Journal Medical Libanais

Volumn 52, Issue 4, 2004, Pages 213-216

  Lewis, Jane M ^a   Osbourne, Audley L M ^b   O'Leary, Michael P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; ANTIHYPERTENSIVE AGENT; APOMORPHINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; NEFAZODONE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; SPIRONOLACTONE; TADALAFIL; TESTOSTERONE; THIAZIDE DIURETIC AGENT; TRAZODONE; VARDENAFIL; YOHIMBINE;

AGITATION; ANXIETY DISORDER; ARTHRALGIA; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DIARRHEA; DIZZINESS; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG USE; DYSPEPSIA; ERECTILE DYSFUNCTION; EVALUATION; FLUSHING; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HEADACHE; HEART PALPITATION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; MALE; NAUSEA; NOSE CONGESTION; PATIENT CARE; PENIS PROSTHESIS; PREVALENCE; PRIAPISM; REVIEW; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; SWEATING; URINE RETENTION; VISUAL DISORDER; VOMITING; YAWNING;

HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS;

EID: 24044464233     PISSN: 00239852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (9)

1. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: The Multinational Survey of the Aging Male (MSAM-7). Eur Urol 2003; 44: 637-49.
2. Berrada S, Kadri N, Mechakra-Tahiri S, Nejjari C. Prevalence of erectile dysfunction and its correlates: A population-based study in Morocco. Int J Impot Res 2003; 15 (Suppl 1): S3-S7.
3. Broderick GA, Lue TF. Evaluation and nonsurgical management of erectile dysfunction and priapism. In: Walsh, editor. Campbell's Urology, 8th ed. Philadelphia: Elsevier, 2002: 1619-71.
4. Kuritzky L. Counseling the patient with erectile dysfunction: A primary care physician perspective. J Am Osteopath Assoc 2002; 102 (Suppl 4): S7-S11.
5. Pallas J, Levine S, Althof S, Risen C. A prospective study of the use of Viagra in a mental health professionals' practice. Unpublished paper presented before the Society for Sex Therapy and Research, Boston, March 5, 1999.
6. Nayal W, Schwarzer U, Klotz T et al. Influences of gym exercises on the penile oxygen pressure. J Urol 1999; 161: A693.
7. Labbate LA, Croft HA, Oleshansky MA. Anti-depressant-related erectile dysfunction: Management via avoidance, switching anti-depressants, antidotes, and adaptation. J Clin Psychiatry 2003; 64 (Suppl 10): 11-19.
8. Seidman SN. The aging male: Androgens, erectile dysfunction, and depression. J Clin Psych 2003; 64 (Suppl 10): S31-S37.
9. Montorsi F, Salonia A, Deho F et al. Pharmacological management of erectile dysfunction. B J U Int 2003; 91: 446-54